HomeCompareTRSBF vs GBDC

TRSBF vs GBDC: Dividend Comparison 2026

TRSBF yields 1.22% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $11.77M in total portfolio value
10 years
TRSBF
TRSBF
● Live price
1.22%
Share price
$2.61
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.08M
Annual income
$7,845,769.56
Full TRSBF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — TRSBF vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRSBFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRSBF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRSBF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRSBF
Annual income on $10K today (after 15% tax)
$103.69/yr
After 10yr DRIP, annual income (after tax)
$6,668,904.13/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $7,314,219.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRSBF + GBDC for your $10,000?

TRSBF: 50%GBDC: 50%
100% GBDC50/50100% TRSBF
Portfolio after 10yr
$14.97M
Annual income
$12,148,251.70/yr
Blended yield
81.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TRSBF
No analyst data
Altman Z
6.9
Piotroski
8/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRSBF buys
0
GBDC buys
0
No recent congressional trades found for TRSBF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRSBFGBDC
Forward yield1.22%11.86%
Annual dividend / share$0.03$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%51.1%
Portfolio after 10y$9.08M$20.85M
Annual income after 10y$7,845,769.56$16,450,733.83
Total dividends collected$8.96M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TRSBF vs GBDC ($10,000, DRIP)

YearTRSBF PortfolioTRSBF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$10,944$243.97$12,492$1,791.70$1.5KGBDC
2$12,209$499.06$16,527$3,160.58$4.3KGBDC
3$14,104$1,040.65$23,588$5,904.90$9.5KGBDC
4$17,339$2,247.09$37,141$11,901.65$19.8KGBDC
5$23,716$5,163.36$66,205$26,463.38$42.5KGBDC
6$38,577$13,200.74$137,452$66,612.65$98.9KGBDC
7$81,413$40,135.71$342,372$195,298.53$261.0KGBDC
8$245,435$158,323.22$1,053,292$686,954.33$807.9KGBDC
9$1,154,758$892,143.08$4,111,439$2,984,416.95$2.96MGBDC
10$9,081,361$7,845,769.56$20,849,974$16,450,733.83$11.77MGBDC

TRSBF vs GBDC: Complete Analysis 2026

TRSBFStock

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Full TRSBF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this TRSBF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRSBF vs SCHDTRSBF vs JEPITRSBF vs OTRSBF vs KOTRSBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.